Texas Children's Hospital And Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization In India

Texas Children Hospital | December 29, 2021

Texas Children's Hospital and Baylor College of Medicine announced today that CORBEVAX™, a protein sub-unit COVID-19 Vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to launch in India with other underserved countries to follow.

Dubbed "The World's COVID-19 Vaccine", it uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children's Hospital CVD, led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine's integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

CORBEVAX™ after completing two Phase III clinical trials involving more than 3000 subjects was found to be safe, well tolerated and immunogenic:

  • CORBEVAX™ demonstrated superior immune response in comparison with COVISHIELD™ vaccine when assessed for Neutralizing Antibody (nAb) Geometric Mean Titers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant. CORBEVAX™ vaccination also generated significant Th1 skewed cellular immune response.
  • CORBEVAX™ nAb GMT against Ancestral-Wuhan strain is indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies.
  • CORBEVAX™ nAb GMT against the Delta strain indicates a vaccine effectiveness of >80 percent for the prevention of symptomatic infections based on published studies.

While none of the subjects who took CORBEVAX™ or COVISHIELD™ had serious adverse events, CORBEVAX™ had 50 percent fewer adverse events than COVISHIELD™.

In the continuous monitoring of phase II studies, CORBEVAX™ showed high persistence of immune response as indicated by <30% drop in nAb GMT till 6 months second dose as compared to >80% drop observed with majority of the vaccines.

"Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world," said Dr. Maria Elena Bottazzi, Professor and Associate Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production."

The need for safe, streamlined, low-cost vaccines for middle- to low-income countries is central to the world's fight against the COVID-19 pandemic. Without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries.

"This announcement is an important first step in vaccinating the world and halting the pandemic. Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant," said Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Widespread and global vaccination with our Texas Children's-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow."

"Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective COVID-19 vaccine. It has now become a reality. We deeply appreciate Texas Children's Hospital Center for Vaccine Development, Baylor, CEPI, the Bill and Melinda Gates Foundation, and the government of India for their continuous support and cooperation during this journey. The combined efforts & unceasing support demonstrate that we can collectively overcome any challenge".

Mahima Datla, Managing Director, Biological E. Limited

Texas Children's Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas, and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston. The organization also created Texas Children's HealthPlan, the nation's first HMO for children; has the largest pediatric primary care network in the country, Texas Children's Pediatrics; Texas Children's Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that's channeling care to children and women all over the world. Texas Children's Global Health program leads efforts that advance health care equity through innovative collaboration in care, education and research for underserved populations globally. Texas Children's Hospital is affiliated with Baylor College of Medicine. 

Texas Children's Hospital Center for Vaccine Development is one of the leading vaccine development centers in the world. Established in Washington DC as the Sabin Vaccine Institute Product Development Partnership (PDP) in the year 2000 and after relocating to the Texas Medical Center in 2011, it rebranded as Texas Children's Center for Vaccine Development. For the past two decades it has acquired an international reputation as a non-profit PDP, advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. In addition, it builds and strengthens capacity for vaccine development locally and with foreign nations and leads global efforts to guide and influence vaccine policy and advocacy through "vaccine diplomacy" as an international bridge for peace and vaccine development capacity.

Baylor College of Medicine Ventures is the commercial engine of the health sciences university, created to support the translation of academic knowledge and intellectual assets for the benefit of society. We do this by engaging university innovators, entrepreneurs and industry to fully develop ideas along their best commercial path. We foster a culture of commercialization and engage with industry to identify market opportunities for collaborative ventures. 

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to over 100 countries and its therapeutic products are sold in India and the USA. BE currently has 8 WHO-prequalified vaccines in its portfolio. In recent years, BE has embarked on new initiatives for organisational expansion such as developing generic injectable products for the regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture APIs sustainably and developing novel vaccines for the global market. 


Check out more information about pediatric emergencies post at . It is the opportunity to have Einstein expertise on your resume. Sign up now!


Check out more information about pediatric emergencies post at . It is the opportunity to have Einstein expertise on your resume. Sign up now!

Related News



SWORD Health | July 05, 2022

Sword Health, the fastest growing digital musculoskeletal (MSK) solution on the market, announced that it is launching a new brand that reflects its mission to free 2 billion people from pain. This change comes at an immense time of progress for the company as it sets its sights on growth in 2023. The new brand position is communicated through a redesigned institutional as well as a modernized logomark composed of two circular shapes representing the company’s focus on every member’s unique journey to a healthier life – the outlined circle represents prevention, and the filled circle treatment. The company will also be softening the look and feel of its digital applications, including the digital therapist and member app. Additionally, its color palette, iconography, photography, member experience, and apparel have all undergone a strategic upgrade to reflect the evolution of Sword Health. "We are announcing the beginning of a global movement to free the world from pain. It's more than just a new look and feel to us, it's the culmination of years of research and development, aimed at supporting the core goal of healing people’s pain. We're confident this movement expresses both the transformation of our company as a whole and the future of a pain-free world." Virgilio Bento, Founder and CEO of SWORD Health Sword Health believes in the power of people to recover at home, without resorting to surgeries or opioids. Since launching in 2015, Sword Health has worked with insurers, health systems and employers worldwide to make high quality physical care accessible to everyone. Sword Health is setting a new standard for clinical outcomes: the company’s results are of a higher quality than the traditional model, and it is delivering real cost savings to their customers while helping their employees heal quickly and safely. About Sword Health Sword Health is the world’s fastest growing digital musculoskeletal (MSK) care provider, on a mission to free 2 billion people from acute, chronic, and post-surgical pain. It is the first digital solution to pair its members with a licensed physical therapist and the Sword Health Digital Therapist, to deliver a clinically-proven, personalized treatment plan that is more effective, easier, and less expensive than the traditional gold standard of care. Sword Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. With the preventative care delivered through Sword+, it is the industry's only end-to-end digital MSK solution. Since launching in 2015, Sword Health has worked with insurers, health systems, and employers in the U.S., Canada, Europe, and Australia to make high quality musculoskeletal care accessible to everyone.

Read More


Atlas Healthcare Partners and MedAxiom Collaborate to Announce a Next-Gen Cardiovascular ASC Solution

Atlas Healthcare Partners | June 29, 2022

An industry first cardiovascular-focused ambulatory surgery center (ASC) business has been formed by Atlas Healthcare Partners and MedAxiom. Atlas Healthcare Partners specializes in creating and operating ambulatory surgery centers (ASCs). By increasing access to top-notch, patient-centered heart care in ASCs, Atlas and MedAxiom will improve cardiovascular care as a whole. With its health system and physician partners, Atlas, the fastest-growing firm in the ASC sector, has a highly integrated strategy that focuses on coordinating doctors and ASCs with the health system's delivery network and plan. "We're very excited about the opportunity to partner with MedAxiom. MedAxiom has an excellent national reputation as the cardiovascular performance management leader. Together, we will bring a new level of cardiovascular ASC expertise and experience to health systems and physicians throughout the country." Aric Burke, Atlas CEO MedAxiom connects cardiovascular programs, leaders, and industry partners to accomplish the Quadruple Aim of high-quality outcomes, lower costs, improved patient experience, and high physician satisfaction. MedAxiom is the pioneer in cardiovascular operational excellence and performance improvement. Through the integration of technology, innovation, and care delivery, MedAxiom is reshaping the future of cardiovascular care. "Our ambition to enhance cardiovascular care and improve heart health demands creative tactics and solid relationships. Atlas is a renowned leader and expert in outpatient care with a clear line of vision towards the development of ASC service lines. Health systems and physicians wishing to enter the outpatient treatment market now have a solution thanks to the combination of Atlas' significant ASC experience and MedAxiom's cardiovascular-specific knowledge." Jerry Blackwell, MD, MBA, FACC, president and CEO of MedAxiom

Read More


ZetrOZ Systems Highlights the Rise in Health Insurance Denials, Provides Solution

ZetrOZ Systems | May 30, 2022

ZetrOZ Systems, leaders in wearable medical technology and makers of the sam® wearable ultrasound device that heals soft tissue, highlighted the rising health insurance claim denials. The organization is encouraging customers to inform themselves about their healthcare policies and challenge the first denial. Millions of people in the U.S. have experienced the devastating denial of their healthcare claims. According to Change Healthcare, 11% of 102 million medical claims at 1,500 hospitals are denied at first. The rate of denials has gone up by 20% since the year 2016. "Unfortunately, medical policies are driven by insurance company profits and fear of change. Thus, patients are often denied advanced new care when they need to access their healthcare benefits for soft tissue injuries." George K. Lewis, Ph.D. and CEO of ZetrOZ Systems "The first 'no' by an insurance policy can be turned into a 'yes' if you are informed and persistent," Lewis continued. "At ZetrOZ, we encourage patients and providers to not simply give up with the first denial of an insurance claim for therapies like Sustained Acoustic Medicine (sam®). Your insurance should always cover treatments that are proven to be both medically effective and cost-effective." If a denial letter is received, consumers can appeal against the decision. Possible issues include inaccurate paperwork, incorrect billing code, misplaced tax ID or wrongly coding the prescription or procedure. Inspite of sam®’s success, it is usually not covered by the first line of treatment. The reason is often an inadequate understanding of the costs and care by patients, insurers, and insurance providers.

Read More